NKCx Histopathological outcome* within 12 months after cervix cytology in 2021 |
511 Trollhättan |
Benign | LSIL | HSIL | AIS | Cancer | Other | PAD missing | Total | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cytologi | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
Benign sample | 45 | 1.0% | 12 | 0.3% | 7 | 0.2% | . | . | . | . | 2 | 0.0% | 4584 | 98.6% | 4650 | 100.0% |
ASCUS | 105 | 22.7% | 95 | 20.5% | 47 | 10.2% | . | . | . | . | 3 | 0.6% | 213 | 46.0% | 463 | 100.0% |
LSIL | 41 | 19.1% | 47 | 21.9% | 45 | 20.9% | . | . | . | . | . | . | 82 | 38.1% | 215 | 100.0% |
Atypical glandular cells/AGC | 4 | 57.1% | 2 | 28.6% | 1 | 14.3% | . | . | . | . | . | . | . | . | 7 | 100.0% |
ASC-H | 14 | 29.8% | 8 | 17.0% | 24 | 51.1% | . | . | . | . | . | . | 1 | 2.1% | 47 | 100.0% |
HSIL | 7 | 10.8% | 6 | 9.2% | 47 | 72.3% | 1 | 1.5% | 3 | 4.6% | . | . | 1 | 1.5% | 65 | 100.0% |
Totalt | 216 | 4.0% | 170 | 3.1% | 171 | 3.1% | 1 | 0.0% | 3 | 0.1% | 5 | 0.1% | 4881 | 89.6% | 5447 | 100.0% |
NOTE: Histopathological outcome from T83x taken into account. |
This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad. |
* Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead. |
The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'. |
Process Registry's Class 1 (benign), 2d (LSIL) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories. |
Snomed codes in the category Cancer: |
---|
M80703, M81403 |